Analysts Set CVRx, Inc. (NASDAQ:CVRX) Price Target at $17.83

Shares of CVRx, Inc. (NASDAQ:CVRX) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $17.83.

CVRX has been the topic of a number of recent analyst reports. Canaccord Genuity Group upped their price objective on CVRx from $22.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, February 5th. Craig Hallum increased their price objective on shares of CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, January 17th. William Blair upgraded shares of CVRx from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 14th. Finally, Piper Sandler upped their target price on shares of CVRx from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, February 5th.

Institutional Investors Weigh In On CVRx

Large investors have recently bought and sold shares of the stock. PharVision Advisers LLC acquired a new stake in CVRx in the 4th quarter worth about $259,000. Two Sigma Investments LP increased its position in shares of CVRx by 80.7% in the 4th quarter. Two Sigma Investments LP now owns 55,367 shares of the company’s stock worth $702,000 after purchasing an additional 24,734 shares during the last quarter. Silvercrest Asset Management Group LLC bought a new position in CVRx during the fourth quarter worth $4,713,000. Parkman Healthcare Partners LLC lifted its holdings in shares of CVRx by 34.9% in the 4th quarter. Parkman Healthcare Partners LLC now owns 921,174 shares of the company’s stock worth $11,671,000 after purchasing an additional 238,277 shares during the last quarter. Finally, Cresset Asset Management LLC grew its position in shares of CVRx by 20.5% during the fourth quarter. Cresset Asset Management LLC now owns 51,102 shares of the company’s stock worth $647,000 after acquiring an additional 8,699 shares during the last quarter. Institutional investors and hedge funds own 75.27% of the company’s stock.

CVRx Stock Up 2.2 %

NASDAQ:CVRX opened at $12.76 on Friday. The company’s 50 day moving average is $14.39 and its two-hundred day moving average is $12.72. The company has a current ratio of 12.06, a quick ratio of 10.23 and a debt-to-equity ratio of 0.69. The company has a market cap of $332.22 million, a PE ratio of -4.74 and a beta of 1.34. CVRx has a twelve month low of $6.40 and a twelve month high of $19.85.

CVRx (NASDAQ:CVRX) last released its quarterly earnings results on Tuesday, February 4th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. Analysts anticipate that CVRx will post -1.91 EPS for the current year.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.